Désiré Collen, MD, PhD

Chairman of the Board

Désiré Collen holds a M.D. degree (1968) and Ph.D. degree in Chemistry (1974) from KULeuven. His team initially developed t-PA, still the most effective drug for thrombolytic therapy of acute myocardial infarction and ischemic stroke.

Désiré Collen has received several scientific awards including the Francqui Prize (1984) and the Health Prize of the Interbrew-Baillet Latour Fund (2006, jointly with P. Carmeliet). He was the Founder and until December 2013 Chairman of the Board of ThromboGenics NV, where his team developed Jetrea for the treatment of vitreo-macular traction. In 2015 he founded Fund+, an investment company, where he is Chairman of the Board of Directors.